CRSP logo

CRISPR Therapeutics AG

CRSP
Healthcare|Biotechnology|CH
$50.07
+1.51 (+3.11%)
Tangible Book / Share
$17.04
Cash / Share
$23.49

About

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Stock Price

-11.6%(1Y)
1M
-0.7%
3M
-6.4%
6M
-8.7%
YTD
-4.5%
1Y
-8.3%
3Y
-8.5%
5Y
-46.8%

Pipeline Summary

21 total trials
15
Phase 1
8
Phase 2
5
Phase 3
0
Phase 4
Terminated: 5By Invitation: 2Completed: 5Recruiting: 5Not Yet Recruiting: 2Active: 2

Active Trials (7)

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1Phase 2Recruiting
Enrollment: 60 participants
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
NCT07758634Hypertension
Phase 1Phase 2Recruiting
Enrollment: 69 participants
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172Cardiovascular
Phase 1Recruiting
Enrollment: 90 participants
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742B-cell Lymphoma
Phase 1Phase 2Recruiting
Enrollment: 120 participants
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease
Phase 3Active
Enrollment: 13 participants

BioScore

5.3/10
Watchlist

Key Facts

Market Cap$4.86B
Employees63 (-84% YoY)
CEOSamarth Kulkarni
IPO DateOct 19, 2016
Beta1.90
52-Week Range$44.12 – $63.45
Avg Volume1,573,434
ExchangeNASDAQ

Ownership

Float99.5%
Shares Outstanding97.0M

Recent Insider Trades

Sakhamuri SivakesavaAWARD
Nov 4, 202690,000 shares @ $51.78
Sakhamuri SivakesavaAWARD
Nov 4, 202640,000 shares
Sakhamuri SivakesavaOTHER
Nov 2, 20260 shares
Silver Andrew JacobAWARD
Oct 26, 202618,000 shares @ $49.01
Silver Andrew JacobAWARD
Oct 26, 20269,000 shares

Peers

BEAMBeam Therapeutics Inc.
$2.73B
DNAGinkgo Bioworks Holdings, Inc.
$760.3M
DTILPrecision BioSciences, Inc.
$292.6M
EDITEditas Medicine, Inc.
$394.7M
MGXMetagenomi, Inc. Common Stock
$26.8M
NTLAIntellia Therapeutics, Inc.
$1.59B
RGNXREGENXBIO Inc.
$503.0M
Data last updated: Nov 9, 2026, 04:04 AM